<DOC>
	<DOCNO>NCT00543504</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Avastin™ give combination 4 study drug/drug combination . It give sunitinib , sorafenib , combination erlotinib cetuximab , combination trastuzumab lapatinib . The safety effectiveness drug combination also study .</brief_summary>
	<brief_title>Bevacizumab Multiple Phase I Combinations</brief_title>
	<detailed_description>The Study Drugs : Bevacizumab ( Avastin™ ) design prevent slow growth cancer cell block growth blood vessel Sunitinib malate ( SutentTM ) design block pathway control important event growth blood vessel vital growth cancer . Sorafenib ( NexavarTM ) design block function important protein cancer cell . These protein , active , part responsible abnormal growth behavior cancer cell . Erlotinib hydrochloride ( TarcevaTM ) design block activity protein find surface many tumor cell may control tumor growth survival . This may stop tumor grow . Cetuximab ( ErbituxTM ) design prevent slow growth cancer cell block protein inside cancer cell , call epidermal growth factor receptor ( EGFR ) . Trastuzumab ( HerceptinTM ) design prevent slow growth cancer cell block protein inside cancer cell , call Her2/neu receptor . Lapatinib ( TykerbTM ) design prevent slow growth cancer cell block protein inside cancer cell , call Her2/neu receptor EGFR . Study Drug Dose Level : If find eligible take part study , doctor decide study drug receive base disease type drug take past . Once decide drug receive , enrol group 3-6 participant receive drug combination . The first group participant receive low dose drug combination . The next group participant receive next high dose drug combination . The third group receive even high dose . This process continue study doctor find high safe dose drug combination . The dose receive depend enrol study safety data available time . The dose receive may lower tolerate study drug combination well . Once high tolerate dose find group , 10 participant add group dose level . The dose level test study drug combination bevacizumab either sunitinib sorafenib close . Study Drug Administration : Avastin™ give needle vein . The first infusion 90 minute . The next infusion may 60 minute first infusion well tolerate . If tolerate second infusion well , third infusion may 30 minute . If take trastuzumab lapatinib Avastin™ , receive Avastin™ every 21 day . If take cetuximab erlotinib Avastin™ , receive Avastin™ every 14 day . If assign take cetuximab erlotinib , cetuximab give vein every week . The first time receive cetuximab , give 2 hour . All infusion give 60 minute . Erlotinib take mouth every day 28-day study cycle . You take erlotinib empty stomach either 1 hour eat 2 hour eat . If assign take trastuzumab lapatinib , trastuzumab give vein every 21-day study cycle . The first infusion 90 minute . If handle infusion well , additional infusion 30 minute Lapatinib take mouth every day 21 day . You take lapatinib empty stomach either 1 hour eat 2 hour eat . Study Visits : Avastin , cetuximab , erlotinib : During Cycle 1 , study visit Weeks 1 2 . During Cycles 2 beyond , study visit Week 1 . At visit , physical exam , blood ( 1 tablespoon ) drawn routine test . If routine urine test do screen abnormal result , urine may collect additional routine test study . After 2 cycle , physical exam every 1-2 month . Every week , blood drawn ( 2 teaspoon ) routine test . During Week 1 cycle , urine collect routine test . After every 2 cycle , CT MRI scan check status disease . After 6 month ( 6 cycle ) study drug treatment , CT MRI scan every 2-4 cycle . Avastin , trastuzumab , lapatinib : During Cycle 1 , study visit Weeks 1 2 . During Cycles 2 beyond , study visit Week 1 . At visit , physical exam , blood ( 1 tablespoon ) drawn routine test . If routine urine test do screen abnormal result , urine may collect additional routine test study . After 2 cycle , physical exam every 1-2 month . During Week 1 cycle , urine collect routine test . After every 2 cycle , CT MRI scan check status disease . After 6 month ( 8 cycle ) study drug treatment , CT MRI scan every 2-4 cycle . Length Study : You may remain study long benefitting . You take study disease get bad intolerable side effect occur . This investigational study . Avastin™ , erlotinib , cetuximab , trastuzumab , lapatinib FDA approve commercially available . Avastin™ FDA approve treatment colorectal cancer lung cancer . Erlotinib FDA approve treatment lung cancer pancreatic cancer . Cetuximab FDA approve treatment colorectal cancer cancer head neck . Trastuzumab FDA approve treatment breast cancer . Lapatinib FDA approve treatment breast cancer . The use drug together investigational authorize use research . Up 354 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy induces CR rate least 10 % improve survival least three month . 2 . Patients must three week prior cytotoxic therapy ; recover blood count eligibility level sooner mucositis acute toxicity , may treat early sooner two week last chemotherapy . Patients must two week five half life biologic therapy , whichever short . 3 . ECOG performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) . 4 . Patients must normal organ marrow function define : absolute neutrophil count &gt; /= 1,000/mL ; platelet &gt; /=75,000/mL ; creatinine &lt; /= 3 X ULN ; total bilirubin &lt; /= 2.0 ; ALT ( SGPT ) &lt; /= 3 X ULN ; Exception patient liver metastasis : total bilirubin &lt; /= 3 x ULN ; ALT ( SGPT ) &lt; /= 5 X ULN . Exception bevacizumab + erlotinib + cetuximab arm bevacizumab + trastuzumab + lapatinib arm : minimum absolute neutrophil count platelet count . 5 . The effect bevacizumab develop human fetus unknown . Angiogenesis critical importance fetal development , bevacizumab likely adverse consequence term fetal development . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day last dose . 6 . Ability understand willingness sign write informed consent document . 7 . Life expectancy least 3 month . 8 . Patients prior DVT/PE eligible treatment receive finish receive appropriate anticoagulation therapy . 1 . Patients hemoptysis within 28 day prior enter study . 2 . Patients clinically significant unexplained bleeding within 28 day prior enter study . 3 . Uncontrolled systemic vascular hypertension ( Systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg medication ) . 4 . Patients clinically significant cardiovascular disease : history CVA within 6 month , myocardial infarction unstable angina within 6 month , unstable angina pectoris . 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic Day 1 . 6 . Pregnant lactating woman . 7 . History hypersensitivity bevacizumab , murine product , component formulation . 8 . ( For patient sunitinib treatment arm trastuzumab/lapatinib treatment arm ) Left ventricular ejection fraction le 50 % unless patient receive angiotensinconverting enzyme ( ACE ) inhibitor / angiotensin receptor blocker ( ARB ) betablocker . 9 . ( For sorafenib treatment arm ) Hypersensitivity sorafenib component formulation . 10 . ( For erlotinib cetuximab treatment arm ) History hypersensitivity erlotinib component formulation . 11 . ( For erlotinib cetuximab treatment arm ) History hypersensitivity cetuximab , murine product , component formulation . 12 . ( For trastuzumab lapatinib treatment arm ) History hypersensitivity trastuzumab , Chinese hamster ovary cell protein , component formulation . 13 . ( For trastuzumab lapatinib treatment arm ) History hypersensitivity lapatinib component formulation . 14 . Patients clinically significant gastrointestinal bleeding within 28 day prior enter study . 15 . Patients hemorrhagic brain metastasis . 16 . Patients prior abdominal surgery within 30 day prior enter study . 17 . ( For patient sunitinib treatment arm trastuzumab/lapatinib treatment arm ) Left ventricular ejection fraction le 50 % , unless patient receive angiotensinconverting enzyme ( ACE ) inhibitor / angiotensin receptor blocker ( ARB ) betablocker . 18 . ( For patient sunitinib treatment arm trastuzumab/lapatinib treatment arm ) QTc prolongation , define great 440 millisecond male , great 460 millisecond female .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>BAY 43-9006</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>SU011248</keyword>
	<keyword>Sutent</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Tykerb</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Erlotinib hydrochloride</keyword>
	<keyword>GW572016</keyword>
	<keyword>Sunitinib Malate</keyword>
</DOC>